Cargando…

Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma

BACKGROUND: The diagnostic performance and prognostic value of serum exosomal glypican 1 (GPC-1) in pancreatic ductal adenocarcinoma (PDAC) remain controversial. In this study, we detected serum exosomal GPC-1 using enzyme-linked immunosorbent assay (ELISA) and determined whether it serves as a pred...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Juan, Guo, Madi, Song, Yushuai, Liu, Shan, Liao, Ran, Zhang, Yu, Zhang, Yumin, Yang, Qi, Gu, Yuanlong, Huang, Xiaoyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614098/
https://www.ncbi.nlm.nih.gov/pubmed/36313694
http://dx.doi.org/10.3389/fonc.2022.992929
_version_ 1784820120839782400
author Zhao, Juan
Guo, Madi
Song, Yushuai
Liu, Shan
Liao, Ran
Zhang, Yu
Zhang, Yumin
Yang, Qi
Gu, Yuanlong
Huang, Xiaoyi
author_facet Zhao, Juan
Guo, Madi
Song, Yushuai
Liu, Shan
Liao, Ran
Zhang, Yu
Zhang, Yumin
Yang, Qi
Gu, Yuanlong
Huang, Xiaoyi
author_sort Zhao, Juan
collection PubMed
description BACKGROUND: The diagnostic performance and prognostic value of serum exosomal glypican 1 (GPC-1) in pancreatic ductal adenocarcinoma (PDAC) remain controversial. In this study, we detected serum exosomal GPC-1 using enzyme-linked immunosorbent assay (ELISA) and determined whether it serves as a predictor of diagnosis and recurrence for early-stage PDAC. METHODS: Serum samples were obtained from patients with 50 PDAC, 6 benign pancreatic tumor (BPT), or 9 chronic pancreatitis (CP) and 50 healthy controls (HCs). Serum exosomes were isolated using an exosome isolation kit. Exosomal and serum GPC-1 levels were measured using ELISA. The freeze–thaw process was carried out to analyze the stability of GPC-1. Receiver operating characteristic (ROC) analysis was employed to assess the diagnostic value of GPC-1. Kaplan–Meier and multivariate Cox analyses were used to evaluate the prognostic value of GPC-1. RESULTS: The average concentrations of serum exosomal and serum GPC-1 were 1.5 and 0.8 ng/ml, respectively. GPC-1 expression levels were stable under repeated freezing and thawing (d1-5 freeze–thaw cycles vs. d0 P > 0.05). Serum exosomal and serum GPC-1 were significantly elevated in patients with PDAC compared with HCs (P < 0.0001) but were slightly higher compared with that in patients with CP and BPT (P > 0.05). The expression levels of exosomal and serum GPC-1 were elevated 5 days after surgery in patients with PDAC, CP, and BPT (P < 0.05). Patients with high levels of exosomal and serum GPC-1 had a shorter relapse-free survival (RFS) (P = 0.006, and P = 0.010). Multivariate analyses showed that serum exosomal and serum GPC-1 were independent prognostic indicators for early RFS (P = 0.008, and P = 0.041). CONCLUSION: ELISA is an effective and sensitive method to detect exosomal and serum GPC-1. The detection of GPC-1 was stable under repeated freezing and thawing cycles and could distinguish early-stage PDAC from HCs but not CP and BPT. Exosomal and serum GPC-1 may be good independent predictors of early recurrence in early-stage PDAC.
format Online
Article
Text
id pubmed-9614098
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96140982022-10-29 Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma Zhao, Juan Guo, Madi Song, Yushuai Liu, Shan Liao, Ran Zhang, Yu Zhang, Yumin Yang, Qi Gu, Yuanlong Huang, Xiaoyi Front Oncol Oncology BACKGROUND: The diagnostic performance and prognostic value of serum exosomal glypican 1 (GPC-1) in pancreatic ductal adenocarcinoma (PDAC) remain controversial. In this study, we detected serum exosomal GPC-1 using enzyme-linked immunosorbent assay (ELISA) and determined whether it serves as a predictor of diagnosis and recurrence for early-stage PDAC. METHODS: Serum samples were obtained from patients with 50 PDAC, 6 benign pancreatic tumor (BPT), or 9 chronic pancreatitis (CP) and 50 healthy controls (HCs). Serum exosomes were isolated using an exosome isolation kit. Exosomal and serum GPC-1 levels were measured using ELISA. The freeze–thaw process was carried out to analyze the stability of GPC-1. Receiver operating characteristic (ROC) analysis was employed to assess the diagnostic value of GPC-1. Kaplan–Meier and multivariate Cox analyses were used to evaluate the prognostic value of GPC-1. RESULTS: The average concentrations of serum exosomal and serum GPC-1 were 1.5 and 0.8 ng/ml, respectively. GPC-1 expression levels were stable under repeated freezing and thawing (d1-5 freeze–thaw cycles vs. d0 P > 0.05). Serum exosomal and serum GPC-1 were significantly elevated in patients with PDAC compared with HCs (P < 0.0001) but were slightly higher compared with that in patients with CP and BPT (P > 0.05). The expression levels of exosomal and serum GPC-1 were elevated 5 days after surgery in patients with PDAC, CP, and BPT (P < 0.05). Patients with high levels of exosomal and serum GPC-1 had a shorter relapse-free survival (RFS) (P = 0.006, and P = 0.010). Multivariate analyses showed that serum exosomal and serum GPC-1 were independent prognostic indicators for early RFS (P = 0.008, and P = 0.041). CONCLUSION: ELISA is an effective and sensitive method to detect exosomal and serum GPC-1. The detection of GPC-1 was stable under repeated freezing and thawing cycles and could distinguish early-stage PDAC from HCs but not CP and BPT. Exosomal and serum GPC-1 may be good independent predictors of early recurrence in early-stage PDAC. Frontiers Media S.A. 2022-10-14 /pmc/articles/PMC9614098/ /pubmed/36313694 http://dx.doi.org/10.3389/fonc.2022.992929 Text en Copyright © 2022 Zhao, Guo, Song, Liu, Liao, Zhang, Zhang, Yang, Gu and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhao, Juan
Guo, Madi
Song, Yushuai
Liu, Shan
Liao, Ran
Zhang, Yu
Zhang, Yumin
Yang, Qi
Gu, Yuanlong
Huang, Xiaoyi
Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma
title Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma
title_full Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma
title_fullStr Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma
title_full_unstemmed Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma
title_short Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma
title_sort serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614098/
https://www.ncbi.nlm.nih.gov/pubmed/36313694
http://dx.doi.org/10.3389/fonc.2022.992929
work_keys_str_mv AT zhaojuan serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma
AT guomadi serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma
AT songyushuai serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma
AT liushan serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma
AT liaoran serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma
AT zhangyu serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma
AT zhangyumin serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma
AT yangqi serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma
AT guyuanlong serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma
AT huangxiaoyi serumexosomalandserumglypican1areassociatedwithearlyrecurrenceofpancreaticductaladenocarcinoma